InflaRx N.V. (IFRX) - What Are Brokerages Thinking About This Stock?

Key Points

• Analyst sentiment is moderately bullish: Nine brokerages give InflaRx a consensus “Moderate Buy” rating, with an average 12-month price target of $7.43 versus the stock’s $1.59 opening price.
• Recent recommendations were mixed, including Cantor Fitzgerald’s higher $6 price target and Needham’s $8 buy target, alongside sell and hold ratings from other analysts.
• InflaRx reported a quarterly loss of $0.11 per share, missing estimates by $0.04. Institutional investors own 42.39% of the company, while analysts expect a full-year loss of approximately $0.31 per share.

Shares of InflaRx N.V. (NASDAQ:IFRX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $7.43.

A number of equities research analysts recently issued reports on the stock. Cantor Fitzgerald upped their price objective on shares of InflaRx from $4.00 to $6.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. Weiss Ratings restated a "sell (d-)" rating on shares of InflaRx in a report on Monday, September 21st. Zacks Research lowered InflaRx from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 25th. Finally, Needham & Company LLC initiated coverage on InflaRx in a research report on Monday, September 14th. They issued a "buy" rating and a $8.00 price target for the company.

InflaRx Stock Performance

Shares of NASDAQ IFRX opened at $1.59 on Tuesday. The business has a 50 day simple moving average of $1.99 and a 200 day simple moving average of $1.89. InflaRx has a 52 week low of $0.80 and a 52 week high of $2.95. The stock has a market cap of $234.32 million, a price-to-earnings ratio of -2.74 and a beta of 2.59.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its earnings results on Friday, August 7th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04). On average, analysts predict that InflaRx will post -0.31 EPS for the current year.

Institutional Trading of InflaRx

Several large investors have recently modified their holdings of the company. Sanctuary Advisors LLC acquired a new stake in shares of InflaRx in the second quarter worth $25,000. AXQ Capital LP acquired a new position in InflaRx during the 2nd quarter valued at $41,000. ADAR1 Capital Management LLC acquired a new position in InflaRx during the 1st quarter valued at $142,000. DCF Advisers LLC acquired a new position in InflaRx during the 2nd quarter valued at $512,000. Finally, Jefferies Financial Group Inc. bought a new stake in InflaRx in the 2nd quarter valued at $1,737,000. 42.39% of the stock is owned by institutional investors.

About InflaRx

InflaRx N.V. NASDAQ: IFRX is a biopharmaceutical company focused on developing therapies for severe and life-threatening inflammatory diseases. Founded in 2007 and headquartered in Jena, Germany, the company's research is centered on the complement system, an important part of the immune system that can contribute to tissue damage when excessively activated.

InflaRx's lead product is vilobelimab, a monoclonal antibody designed to selectively block the complement protein C5a while preserving other components of the immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.